A detailed history of Bvf Inc transactions in Xencor Inc stock. As of the latest transaction made, Bvf Inc holds 850,000 shares of XNCR stock, worth $20.6 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
850,000
Holding current value
$20.6 Million
% of portfolio
0.54%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.7 - $21.65 $13.3 Million - $18.4 Million
850,000 New
850,000 $17.1 Million
Q1 2021

May 17, 2021

SELL
$40.81 - $53.88 $51.6 Million - $68.1 Million
-1,264,754 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$36.63 - $47.63 $29.4 Million - $38.3 Million
-803,344 Reduced 38.84%
1,264,754 $55.2 Million
Q2 2020

Aug 14, 2020

BUY
$27.76 - $33.42 $10.5 Million - $12.7 Million
378,798 Added 22.42%
2,068,098 $67 Million
Q1 2020

May 15, 2020

BUY
$20.69 - $37.79 $35 Million - $63.8 Million
1,689,300 New
1,689,300 $50.5 Million
Q2 2019

Aug 14, 2019

SELL
$29.6 - $40.93 $26,758 - $37,000
-904 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$27.85 - $38.09 $16.5 Million - $22.6 Million
-592,561 Reduced 99.85%
904 $28,000
Q4 2018

Feb 14, 2019

SELL
$32.39 - $42.05 $7.91 Million - $10.3 Million
-244,073 Reduced 29.14%
593,465 $21.5 Million
Q3 2018

Nov 14, 2018

SELL
$35.69 - $47.65 $1.15 Million - $1.53 Million
-32,107 Reduced 3.69%
837,538 $32.6 Million
Q2 2018

Aug 14, 2018

SELL
$28.41 - $42.41 $919,205 - $1.37 Million
-32,355 Reduced 3.59%
869,645 $32.2 Million
Q1 2018

May 07, 2018

BUY
$21.18 - $33.78 $19.1 Million - $30.5 Million
902,000 New
902,000 $27 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.45B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.